Abstract
Colon, breast and lung adenocarcinomas - three of the major malignancies occurring in humans, together with ovarian, endometrial, kidney and liver adenocarcinomas, account for more then 50% of cancerrelated death. As the number of cancer-related deaths has not decreased in recent years, major efforts are being made to find new and more specific drugs for cancer treatment. One of the approaches developed in recent years for targeted cancer therapy is the construction and use of chimeric proteins. Chimeric cytotoxins are a class of targeted molecules designed to recognize and specifically destroy cells over-expressing specific receptors. These molecules, designed and constructed by gene fusion techniques, comprise both the cell-targeting and the cell-killing moieties. Our laboratory has developed a number of chimeric proteins based on an analog of Gonadotropin Releasing Hormone (GnRH) as their targeting moiety. These chimeras recognize a GnRH-binding site that, we found, was over-expressed on a surprisingly wide variety of cancers, all confined to the adenocarcinoma type. A GnRH analog was fused to a large number of killing moieties, including bacterial or human pro-apoptotic proteins. All GnRH-based chimeric proteins selectively killed adenocarcinoma cells both in vitro and in vivo. Utilizing GnRH-based chimeric proteins for targeted therapy could open up new vistas in the fight against adenocarcinomas in humans. This review summarizes the latest developments in the area of targeted cancer therapy via specific antigens/receptors, as well as our latest findings in targeting GnRH-binding sites using GnRH-based chimeric proteins for specific and targeted adenocarcinoma therapy in humans.
Keywords: targeted therapy, cancer, chimeric proteins, adenocarcinoma, gnrh-binding site, apoptosis
Current Cancer Drug Targets
Title: Surface Antigens/Receptors for Targeted Cancer Treatment: The GnRH Receptor / Binding Site for Targeted Adenocarcinoma Therapy
Volume: 4 Issue: 8
Author(s): R. Eaveri, A. Ben-Yehudah and H. Lorberboum-Galski
Affiliation:
Keywords: targeted therapy, cancer, chimeric proteins, adenocarcinoma, gnrh-binding site, apoptosis
Abstract: Colon, breast and lung adenocarcinomas - three of the major malignancies occurring in humans, together with ovarian, endometrial, kidney and liver adenocarcinomas, account for more then 50% of cancerrelated death. As the number of cancer-related deaths has not decreased in recent years, major efforts are being made to find new and more specific drugs for cancer treatment. One of the approaches developed in recent years for targeted cancer therapy is the construction and use of chimeric proteins. Chimeric cytotoxins are a class of targeted molecules designed to recognize and specifically destroy cells over-expressing specific receptors. These molecules, designed and constructed by gene fusion techniques, comprise both the cell-targeting and the cell-killing moieties. Our laboratory has developed a number of chimeric proteins based on an analog of Gonadotropin Releasing Hormone (GnRH) as their targeting moiety. These chimeras recognize a GnRH-binding site that, we found, was over-expressed on a surprisingly wide variety of cancers, all confined to the adenocarcinoma type. A GnRH analog was fused to a large number of killing moieties, including bacterial or human pro-apoptotic proteins. All GnRH-based chimeric proteins selectively killed adenocarcinoma cells both in vitro and in vivo. Utilizing GnRH-based chimeric proteins for targeted therapy could open up new vistas in the fight against adenocarcinomas in humans. This review summarizes the latest developments in the area of targeted cancer therapy via specific antigens/receptors, as well as our latest findings in targeting GnRH-binding sites using GnRH-based chimeric proteins for specific and targeted adenocarcinoma therapy in humans.
Export Options
About this article
Cite this article as:
Eaveri R., Ben-Yehudah A. and Lorberboum-Galski H., Surface Antigens/Receptors for Targeted Cancer Treatment: The GnRH Receptor / Binding Site for Targeted Adenocarcinoma Therapy, Current Cancer Drug Targets 2004; 4 (8) . https://dx.doi.org/10.2174/1568009043332745
DOI https://dx.doi.org/10.2174/1568009043332745 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Density Functional Theory, Docking, Bioisosteric Replacement, Pharmacophore Perception, Physical Chemical Analyses of the Interactions of Novel PIM-1 Inhibitors with Suitable Pharmacokinetic Properties for Cancer Treatment
Current Physical Chemistry Let-7a Could Serve as A Biomarker for Chemo-Responsiveness to Docetaxel in Gastric Cancer
Anti-Cancer Agents in Medicinal Chemistry Plants vs. Cancer: A Review on Natural Phytochemicals in Preventing and Treating Cancers and Their Druggability
Anti-Cancer Agents in Medicinal Chemistry Immunotherapeutic Options for Pediatric Malignancies
Current Immunology Reviews (Discontinued) Effect of DNA Repair Deficiencies on the Cytotoxicity of Drugs Used in Cancer Therapy - A Review
Current Medicinal Chemistry microRNA-133: Expression, Function and Therapeutic Potential in Muscle Diseases and Cancer
Current Drug Targets A Novel Information Theoretic Approach to Gene Selection for Cancer Classification Using Microarray Data
Current Bioinformatics Patent Selections
Recent Patents on Biomarkers Gold Nanoparticles - Synthesis and Applications in Cancer Management
Recent Patents on Materials Science How to Target Activated Ras Proteins: Direct Inhibition vs. Induced Mislocalization
Mini-Reviews in Medicinal Chemistry Partial Reprogramming As An Emerging Strategy for Safe Induced Cell Generation and Rejuvenation
Current Gene Therapy Role of Calcium, Vitamin D, and the Extrarenal Vitamin D Hydroxylases in Carcinogenesis
Anti-Cancer Agents in Medicinal Chemistry An Expanding Appreciation of the Role Chemokine Receptors Play in Cancer Progression
Current Pharmaceutical Design Recent Advances in the Chemistry and Pharmacological Activity of New Steroidal Antiandrogens and 5α-Reductase Inhibitors
Current Medicinal Chemistry Viral Envelope Membrane: A Special Entry Pathway and a Promising Drug Target
Current Medicinal Chemistry Role of Netrin-1 Beyond the Brain: From Biomarker of Tissue Injury to Therapy for Inflammatory Diseases
Recent Patents on Biomarkers Current Prodrug Design for Drug Discovery
Current Pharmaceutical Design Selenium-Rich Foods: a Promising Approach to Colorectal Cancer Prevention
Current Pharmaceutical Biotechnology Pharmacology of TRP Channels in the Vasculature
Current Vascular Pharmacology The Growth Hormone Secretagogue Receptor (Ghs-R)
Current Pharmaceutical Design